Detalhe da pesquisa
1.
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
Diabetes Obes Metab
; 2024 Apr 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38679838
2.
Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.
Am J Nephrol
; 54(1-2): 74-82, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36754023
3.
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Diabetes Obes Metab
; 24(9): 1753-1761, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35546279
4.
Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study.
J Med Virol
; 93(5): 2925-2931, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33463731
5.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Lancet
; 394(10193): 131-138, 2019 07 13.
Artigo
Inglês
| MEDLINE | ID: mdl-31189509
6.
A cross-sectional community-based observational study of asymptomatic SARS-CoV-2 prevalence in the greater Indianapolis area.
J Med Virol
; 92(11): 2874-2879, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32543722
7.
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
Diabetes Obes Metab
; 21(6): 1493-1497, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30762290
8.
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Diabetes Obes Metab
; 20(8): 2023-2028, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29603872
9.
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Diabetes Obes Metab
; 19(3): 436-441, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27766728
10.
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Cardiovasc Diabetol
; 15: 38, 2016 Feb 24.
Artigo
Inglês
| MEDLINE | ID: mdl-26912057
11.
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Diabetes Metab Res Rev
; 32(8): 776-790, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27102969
12.
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
Diabetes Obes Metab
; 18(11): 1138-1142, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27265893
13.
Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
Diabetes Care
; 46(8): 1524-1530, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37343574
14.
Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats.
Am J Physiol Renal Physiol
; 300(3): F749-55, 2011 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21209009
15.
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
Kidney360
; 2(2): 254-262, 2021 02 25.
Artigo
Inglês
| MEDLINE | ID: mdl-35373017
16.
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Lancet Diabetes Endocrinol
; 8(2): 106-114, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31924562
17.
The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
J Med Econ
; 22(5): 447-454, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30736708
18.
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
Diabetes Ther
; 9(2): 637-650, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29460259
19.
Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
Clin Ther
; 40(8): 1396-1407, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30093131
20.
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Endocrinol
; 6(8): 605-617, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29910024